Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 34 | 56 | 73 | 292 | 334 | 393 | 426 | 327 | 376 | 290 | 428 | 449 |
| Expenses | 72 | 67 | 76 | 228 | 257 | 251 | 243 | 239 | 269 | 273 | 336 | 326 |
| Operating Profit | -39 | -10 | -3 | 64 | 77 | 142 | 183 | 88 | 106 | 17 | 92 | 123 |
| OPM % | -114% | -19% | -3.8% | 22% | 23% | 36% | 43% | 27% | 28% | 6% | 21% | 27% |
| Other Income | -32 | -74 | 3 | -1 | -1 | -94 | 2 | 2 | 3 | -2 | 2 | -0 |
| Interest | 25 | 26 | 20 | 42 | 45 | 46 | 33 | 27 | 34 | 38 | 23 | 31 |
| Depreciation | 18 | 20 | 20 | 68 | 68 | 69 | 68 | 68 | 70 | 70 | 72 | 72 |
| Profit before tax | -114 | -130 | -40 | -47 | -37 | -67 | 83 | -4 | 6 | -93 | -0 | 20 |
| Tax % | 0% | 0% | 0% | -88% | 12% | 4% | -19% | -96% | -83% | -5% | -1,630% | -23% |
| Net Profit | -114 | -130 | -40 | -6 | -42 | -69 | 98 | -0 | 10 | -89 | 5 | 25 |
| EPS in Rs | -6.02 | 8.61 | -0.02 | 0.92 | -7.74 | 0.40 | 2.18 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales | 21 | 132 | 39 | 172 | 1,445 | 1,422 | 1,543 |
| Expenses | 93 | 229 | 199 | 254 | 978 | 1,117 | 1,204 |
| Operating Profit | -71 | -97 | -161 | -82 | 467 | 304 | 339 |
| OPM % | -334% | -73% | -415% | -48% | 32% | 21% | 22% |
| Other Income | 1 | 4 | -526 | -143 | -94 | 5 | 2 |
| Interest | 16 | 68 | 48 | 89 | 166 | 122 | 126 |
| Depreciation | 34 | 70 | 66 | 76 | 274 | 279 | 283 |
| Profit before tax | -121 | -231 | -800 | -391 | -68 | -92 | -67 |
| Tax % | 0% | -0% | 0% | 0% | -73% | -20% | |
| Net Profit | -121 | -231 | -800 | -391 | -18 | -74 | -49 |
| EPS in Rs | -1.57 | -6.44 | -4.24 | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 131% | 232% | 4% | ||
| Compounded Profit Growth | % | 8% | 24% | -142% | ||
| Stock Price CAGR | % | % | % | -14% | ||
| Return on Equity | % | -10% | -3% | -1% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 3 | 4 | 4 | 11 | 11 |
| Reserves | 774 | 1,009 | 781 | 392 | 5,869 | 5,820 |
| Borrowings | 386 | 1,154 | 864 | 562 | 772 | 1,276 |
| Other Liabilities | 96 | 276 | 365 | 468 | 1,005 | 1,197 |
| Total Liabilities | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,304 |
| Fixed Assets | 633 | 1,231 | 1,361 | 863 | 6,118 | 6,017 |
| CWIP | 431 | 490 | 334 | 188 | 218 | 529 |
| Investments | 0 | 0 | 4 | 20 | 16 | 16 |
| Other Assets | 195 | 722 | 314 | 356 | 1,305 | 1,742 |
| Total Assets | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,304 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity | -118 | -416 | -163 | -107 | -68 | 9 |
| Cash from Investing Activity | -207 | -692 | -68 | 511 | -201 | -495 |
| Cash from Financing Activity | 381 | 1,162 | 118 | -391 | 412 | 359 |
| Net Cash Flow | 56 | 54 | -112 | 13 | 143 | -127 |
| Free Cash Flow | -325 | -1,071 | -207 | -171 | -196 | -561 |
| CFO/OP | 164% | 430% | 108% | 130% | -13% | 6% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 38 | 65 | 36 | 117 | 105 | 177 |
| Inventory Days | 87 | 1,805 | 615 | 258 | 222 | 438 |
| Days Payable | 762 | 410 | 420 | 163 | 147 | 307 |
| Cash Conversion Cycle | -637 | 1,461 | 232 | 212 | 180 | 308 |
| Working Capital Days | -2,392 | -1,291 | -6,745 | -877 | -58 | -6 |
| ROCE % | -10% | -12% | -12% | 6% | 1% |
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|
| Promoters | 37.76% | 34.25% | 29.78% | 29.77% | 29.93% | 30.48% | 30.48% |
| FIIs | 17.44% | 18.54% | 18.69% | 19.39% | 19.24% | 17.50% | 19.19% |
| DIIs | 12.56% | 18.03% | 18.09% | 18.48% | 18.80% | 20.61% | 23.37% |
| Public | 32.24% | 29.17% | 33.42% | 32.34% | 32.01% | 31.40% | 26.95% |
| No. of Shareholders | 98,425 | 82,712 | 87,760 | 87,416 | 84,595 | 79,460 | 77,899 |
Fundamentals
Market Cap₹ 18,156 Cr.
Current Price₹ 1,583
Book Value₹ 509
ROCE0.59 %
ROE-1.09 %
Dividend Yield0.00 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)4%
Compounded Profit Growth (TTM)-142%
Consolidated figures.
Valuation
Market capRs 17,293 Cr
Enterprise valueRs 18,277 Cr
Price to book17.08x
Price to sales11.20x
EV / EBITDA53.55x
EV / EBIT313.88x
EV / sales11.84x
Earnings yield-0.28%
Profitability
Operating margin (excl. other income)-73.16%
Operating margin (incl. other income)-70.30%
EBITDA margin22.11%
Pre-tax margin-4.36%
Net profit margin-3.15%
Net margin, latest quarter5.57%
ROE-25.85%
ROCE-9.81%
ROA-12.49%
ROIC (approx.)2.91%
Tax rate0.05%
Other income / net worth0.37%
Growth
Sales growth (latest year)517.72%
Sales growth QoQ4.86%
Profit growth QoQ443.48%
Sales growth YoY (latest quarter)37.20%
Per share
EPS (TTM)Rs -4.24
EPS (latest year)Rs -59.13
EPS (latest quarter)Rs 2.18
Book value per shareRs 88.29
Sales per shareRs 134.59
Cash flow per shareRs -36.27
Free cash flow per shareRs -48.92
Efficiency
Asset turnover0.05x
Fixed asset turnover0.11x
Inventory turnover0.39x
Inventory days947 days
Debtor days65 days
Debtors turnover5.59x
Creditor days307 days
Cash conversion cycle308 days
Working capital days-6 days
Leverage
Total debtRs 1,154 Cr
Cash and bankRs 170 Cr
Net debtRs 985 Cr
Debt to equity1.14x
Net debt / EBITDA2.88x
Interest coverage0.46x
Current ratio (filing 2026-03-31)0.99x
Quick ratio (filing 2026-03-31)0.68x
Trade payables (filing 2026-03-31)Rs 375 Cr
Owners' fund to total sources41.46%
Debt to assets47.26%
Cash flow
Cash from Operating Activity (latest year)Rs -416 Cr
Cash from Investing Activity (latest year)Rs -692 Cr
Cash from Financing Activity (latest year)Rs 1,162 Cr
Net Cash Flow (latest year)Rs 54 Cr
Free cash flow (latest year)Rs -561 Cr
FCFE (approx.: FCF + change in debt)Rs 207 Cr
Statement figures
Net sales (TTM)Rs 1,543 Cr
Net sales (latest year)Rs 132 Cr
Sales (latest quarter)Rs 449 Cr
Operating profit excl. other income (latest year)Rs -97 Cr
Operating profit (latest quarter)Rs 123 Cr
Other income (TTM)Rs 2 Cr
EBITDA (TTM)Rs 341 Cr
PBDT (TTM)Rs 216 Cr
Profit before tax (TTM)Rs -67 Cr
Tax (latest year)Rs -0 Cr
Net profit (TTM)Rs -49 Cr
Net profit (latest year)Rs -231 Cr
Net profit (latest quarter)Rs 25 Cr
Depreciation (TTM)Rs 283 Cr
Depreciation (latest quarter)Rs 72 Cr
Interest (TTM)Rs 126 Cr
Cost of goods sold (latest year)Rs 106 Cr
Total expenditure (latest year)Rs 229 Cr
Total income (latest year)Rs 136 Cr
Share capitalRs 3 Cr
ReservesRs 1,009 Cr
Shareholders' fundsRs 1,012 Cr
Total assetsRs 2,442 Cr
Net blockRs 1,231 Cr
Capital work in progressRs 490 Cr
ReceivablesRs 24 Cr
InventoryRs 275 Cr
Other liabilitiesRs 276 Cr
Shares outstanding (crore)11.47
Ownership
Promoter holding30.48% (+0.70 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | ONESOURCE | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -5.4% | -2.8% | -2.7 pts |
| 1 month | -1.3% | -6.8% | +5.5 pts |
| 3 months | -9.6% | -7.6% | -2.0 pts |
| 6 months | +2.4% | +0.4% | +1.9 pts |
| 1 year | -13.6% | -9.9% | -3.7 pts |
86 mutual fund schemes hold about ₹2,933 Cr.
Over three months 22 bought more and 25 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| Motilal Oswal Large & Midcap Fund | 2.81% | 565 | -11% |
| Motilal Oswal Large & Midcap Fund | 2.81% | 517 | -11% |
| Motilal Oswal Flexi Cap Fund | 2.56% | 363 | -1% |
| Motilal Oswal ELSS Tax Saver Fund | 3.23% | 166 | -14% |
| 360 ONE Focused Fund | 2.36% | 161 | +36% |
| Axis Small Cap Fund | 0.44% | 139 | -5% |
| Mirae Asset Healthcare Fund | 2.96% | 105 | -2% |
| Axis Flexi Cap Fund | 0.66% | 91 | -2% |
| Axis Flexi Cap Fund | 0.66% | 88 | -2% |
| Bandhan Small Cap Fund | 0.23% | 80 | -8% |
| Motilal Oswal Small Cap Fund | 0.94% | 76 | -10% |
| Aditya Birla SL Flexi Cap Fund | 0.25% | 74 | -6% |
| Aditya Birla SL Value Fund | 0.97% | 67 | -3% |
| Mirae Asset Aggressive Hybrid Fund | 0.55% | 53 | +11% |
| 360 ONE Flexicap Fund | 1.59% | 36 | +2% |
| Bajaj Finserv Flexi Cap Fund | 0.36% | 30 | +100% |
| JM Flexi Cap Fund | 0.56% | 29 | -5% |
| Bajaj Finserv Small Cap Fund | 0.80% | 21 | +100% |
| Nippon India Nifty Smallcap 250 Index Fund | 0.54% | 19 | -2% |
| Motilal Oswal Active Momentum Fund | 1.64% | 19 | +98% |
| Mirae Asset Multi Asset Allocation Fund | 0.50% | 18 | +6% |
| JM Small Cap Fund | 1.93% | 18 | -11% |
| JM Mid Cap Fund | 1.21% | 16 | -4% |
| Bajaj Finserv Multi Asset Allocation Fund | 0.64% | 12 | +100% |
| TRUSTMF Flexi Cap Fund | 1.16% | 12 | +26% |
Red flags
F-score 3 of 8| explain | Receivables outrunning sales Receivables grew 965% vs sales +518% in 2026 |
| explain | Debt up, profit down Borrowings up 199% while net profit fell in 2026 |
| look | Inventory outrunning sales Inventory grew 5534% vs sales +518% in 2026 |
| look | Share dilution Share count up 2433% in a year |
| look | Repeated losses Net loss in each of the last two years |
| look | Auditor change Auditor change 2026-09-23: Onesource Specialty Pharma Limited has informed the Exchange regarding Change in Auditors of the company. |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹449 Cr +37.3% vs Jun 2025.
Net profit ₹25 Cr.
Against our estimate for Jun 2026: sales +57.6%, profit +1402.2% in line. Our estimate for Sep 2026: sales Rs 447 Cr, profit Rs 9 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
EPS in the scrip is zero (4 trailing quarters)
Quick answers
What is the market cap of OneSource Specialty Pharma Ltd?
OneSource Specialty Pharma Ltd (ONESOURCE) has a market capitalisation of Rs 18,156 Cr. at the 2026-10-01 close.
What were OneSource Specialty Pharma Ltd's latest quarterly results?
In the Jun 2026 quarter, OneSource Specialty Pharma Ltd sales was Rs 449 Cr (+37.3% vs Jun 2025) and net profit was Rs 25 Cr.
What is the 52-week high and low of OneSource Specialty Pharma Ltd?
The 52-week high is Rs 1,925.00 and the 52-week low is Rs 1,057.00.